BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Mar 31, 2026. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 31, 2026 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · (Except share data)
(Except share data)
| Year ended | ||
|---|---|---|
| December 31, | ||
| 2025 | 2024 | |
| U.S. $ in thousands | ||
| Operating expenses: | ||
| Research and development | $4,175 | $4,651 |
| General and administrative | 5,778 | 7,042 |
| Operating loss | (9,953) | (11,693) |
| Financial expense, net | 533 | 77 |
| Gain on change in fair value of Warrants liability (Note 7) | 179 | 147 |
| Net loss | $(10,307) | $(11,623) |
| Basic and diluted net loss per share | $(1.11) | $(2.31) |
| Weighted average number of shares outstanding used in computing basic and diluted net loss per share | 9,268,976 | 5,021,798 |
The accompanying notes are an integral part of the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.